Skip to main content

Table 2 Hazard ratios of overall mortality and distant disease according to tertiles of serum 25(OH)D

From: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

 

Serum 25(OH)D

 

Continuous

Categorized

 

per 10 nmol/L decrement

< 35 nmol/L

35-55 nmol/L

≥ 55 nmol/L

Outcome

No.

(events)

HR

95% CI

P trend a

No.

(events)

HR

95% CI

No.

(events)

HR

95% CI

No.

(events)

HR

95% CI

Overall mortality

             

   Crude†b

1,295 (183)

1.11

1.03 to 1.18

0.009

432 (87)

1.96

1.32 to 2.90

407 (46)

0.94

0.62 to 1.44

456 (50)

1.00

-

   Multivariate‡c

1,265 (174)

1.08

1.00 to 1.17

0.07

422 (82)

1.55

1.00 to 2.39

397 (44)

0.72

0.45 to 1.17

446 (48)

1.00

-

Distant disease

             

   Crudeb

1,088 (137)

1.12

1.03 to 1.21

0.01

341 (64)

2.09

1.31 to 3.30

347 (37)

1.19

0.73 to 1.93

400 (36)

1.00

-

   Multivariatec

1,074 (135)

1.14

1.05 to 1.24

0.006

338 (63)

2.09

1.29 to 3.41

342 (37)

1.16

0.70 to 1.94

394 (35)

1.00

-

  1. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; HR, hazard ratio.
  2. a Calculated by using serum 25(OH)D as a continuous variable.
  3. b Stratified by age at diagnosis and season.
  4. c Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection; due to missing covariate values, 30 observations were not included in the multivariate model.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us